Polaryx Therapeutics presents PLX-200 development update at NCL conference
PLYX•
PLYX•Polaryx Therapeutics presented its PLX-200 program at the NCL conference on November 13, including previously published preclinical findings. PLX-200 is being evaluated in the SOTERIA Phase 2 trial, whose first site recently opened at Boys Town National Research Hospital.
Polaryx Therapeutics presented its PLX-200 development program at the NCL conference in Quincy, Massachusetts, held November 11-13, 2026. Chief Medical Officer Will Charlton's November 13 presentation included previously published preclinical findings in a CLN3 mouse model. PLX-200 is being evaluated in the SOTERIA Phase 2 basket trial across four rare pediatric lysosomal storage disorders, and its first trial site recently activated at Boys Town National Research Hospital in Nebraska. Polaryx also sponsored and attended NTSAD's Imagine & Believe fundraiser on November 12 in the Boston area.